Then, the Tumor Immune Dysfunction and Exclusion (TIDE) algorithm and SubMap were applied to predict the clinical response to immune checkpoint blockade (CTLA-4, PD-1, and PD-L1) in different subgroups. This evidence concerns the gene CTLA4 and neoplasm.